Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Capital Expenditures (2018 - 2026)

DiaMedica Therapeutics filings provide 9 years of Capital Expenditures readings, the most recent being $8000.0 for Q1 2026.

  • Quarterly Capital Expenditures fell 33.33% to $8000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $36000.0 through Mar 2026, up 28.57% year-over-year, with the annual reading at $40000.0 for FY2025, 60.0% up from the prior year.
  • Capital Expenditures hit $8000.0 in Q1 2026 for DiaMedica Therapeutics, up from $6000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $43000.0 in Q3 2022 and bottomed at $3000.0 in Q4 2023.
  • Average Capital Expenditures over 5 years is $11866.7, with a median of $8000.0 recorded in 2026.
  • The largest annual shift saw Capital Expenditures skyrocketed 2050.0% in 2022 before it plummeted 90.62% in 2023.
  • DiaMedica Therapeutics' Capital Expenditures stood at $32000.0 in 2022, then plummeted by 90.62% to $3000.0 in 2023, then skyrocketed by 133.33% to $7000.0 in 2024, then fell by 14.29% to $6000.0 in 2025, then surged by 33.33% to $8000.0 in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Capital Expenditures are $8000.0 (Q1 2026), $6000.0 (Q4 2025), and $16000.0 (Q3 2025).